Restrospective reappraisal of the prognostic classification of spitzoid melanocytic neoplasms after BRAF and NRAS mutation characterisation: a single institution experience.
BRAF
FISH
NGS
NRAS
Spitz melanoma
Spitz tumour
Spitzoid melanoma
next-generation sequencing
Journal
Histopathology
ISSN: 1365-2559
Titre abrégé: Histopathology
Pays: England
ID NLM: 7704136
Informations de publication
Date de publication:
26 Feb 2024
26 Feb 2024
Historique:
revised:
07
02
2024
received:
02
10
2023
accepted:
09
02
2024
medline:
27
2
2024
pubmed:
27
2
2024
entrez:
27
2
2024
Statut:
aheadofprint
Résumé
The current WHO classification of melanocytic tumours excludes neoplasms showing BRAF or NRAS mutations from the Spitz category. This study aimed to review and reclassify atypical melanocytic tumours with spitzoid morphological features diagnosed between 2009 and 2021 in our hospital after expanding the molecular profile, including BRAF and NRAS mutations in all cases. A total of 71 neoplasms showing spitzoid features (Spitz-like) and atypia were included. The risk of progression of tumours was first studied by integrating the morphology, immunohistochemistry (p16, Ki67, HMB45 and PRAME) and fluorescence in-situ hybridisation (FISH) results (melanoma multiprobe and 9p21). In a second step, after expanding the molecular study, including BRAF and NRAS mutational status, the neoplasms were finally classified into four subgroups: atypical Spitz tumour (AST, n = 45); BRAF-mutated naevus/low-grade melanocytoma with spitzoid morphology (BAMS, n = 2); Spitz melanoma (SM, n = 14); and BRAF or NRAS mutated melanoma with spitzoid features (MSF, n = 10). Follow-up of patients revealed uneventful results for AST and BAMS. Only one SM presented lymph node metastasis after 134 months. Conversely, patients with MSF showed an unfavourable outcome: three developed lymph node metastases after a mean time of 22 months, with one patient presenting distant metastasis and dying of the disease 64 months from diagnosis. The progression-free survival showed significant differences between the four groups of spitzoid tumours (P < 0.001) and between both melanoma subtypes (P = 0.012). The classification and prognostication of atypical neoplasms with spitzoid features requires the integration of histomorphology with the molecular investigation of tumours, which should include BRAF and NRAS mutational status.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : HORIZON EUROPE Health
Organisme : European Union's Horizon Europe Research and Innovation Programme
ID : 101096667
Informations de copyright
© 2024 John Wiley & Sons Ltd.
Références
Spitz S. Melanomas of childhood. Am. J. Pathol. 1948; 24; 591-609.
Gerami P, Busam K, Cochran A et al. Histomorphologic assessment and interobserver diagnostic reproducibility of atypical spitzoid melanocytic neoplasms with long-term follow-up. Am. J. Surg. Pathol. 2014; 38; 934-940.
Massi D, Cesinaro AM, Tomasini C et al. Atypical Spitzoid melanocytic tumors: a morphological, mutational, and FISH analysis. J. Am. Acad. Dermatol. 2011; 64; 919-935.
Elder DE, Bastian BC, Cree IA, Massi D, Scolyer RA. The 2018 World Health Organization classification of cutaneous, mucosal, and uveal melanoma detailed analysis of 9 distinct subtypes defined by their evolutionary pathway. Arch. Pathol. Lab. Med. 2020; 144; 500-522.
Barnhill RL. The Spitzoid lesion: rethinking Spitz tumors, atypical variants, ‘Spitzoid melanoma’ and risk assessment. Mod. Pathol. 2006; 19; S21-S33.
Wiesner T, He J, Yelensky R et al. Kinase fusions are frequent in Spitz tumours and spitzoid melanomas. Nat. Commun. 2014; 5; 3116.
Raghavan SS, Peternel S, Mully TW et al. Spitz melanoma is a distinct subset of spitzoid melanoma. Mod. Pathol. 2020; 33; 1122-1134.
Quan VL, Zhang B, Zhang Y et al. Integrating next-generation sequencing with morphology improves prognostic and biologic classification of Spitz neoplasms. J. Invest. Dermatol. 2020; 140; 1599-1608.
Pappo AS, McPherson V, Pan H et al. A prospective, comprehensive registry that integrates the molecular analysis of pediatric and adolescent melanocytic lesions. Cancer 2021; 127; 3825-3831.
Harms PW, Hocker TL, Zhao L et al. Loss of p16 expression and copy number changes of CDKN2A in a spectrum of spitzoid melanocytic lesions. Hum. Pathol. 2016; 58; 152-160.
Lezcano C, Jungbluth AA, Nehal KS, Hollmann TJ, Busam KJ. PRAME expression in melanocytic tumors. Am. J. Surg. Pathol. 2018; 42; 1456-1465.
Kunc M, Żemierowska N, Skowronek F, Biernat W. Diagnostic test accuracy meta-analysis of PRAME in distinguishing primary cutaneous melanomas from benign melanocytic lesions. Histopathology 2023; 83; 3-14.
Díaz A, Valera A, Carrera C et al. Pigmented spindle cell naevus: clues for differentiating it from spindle cell malignant melanoma. A comprehensive survey including clinicopathologic, immunohistochemical, and FISH studies. Am. J. Surg. Pathol. 2011; 35; 1733-1742.
Moysset I, Fuster-Anglada C, Castillo P et al. Immunophenotype of tumor-infiltrating lymphocytes in atypical Spitzoid tumors according to the risk of progression. Ann. Diagn. Pathol. 2022; 60; 151985.
Yeh I, de la Fouchardiere A, Pissaloux D et al. Clinical, histopathologic, and genomic features of spitz tumors with ALK fusions. Am. J. Surg Pathol. 2015; 39; 581-591.
Yeh I, Busam KJ, McCalmont TH et al. Filigree-like rete ridges, lobulated nests, rosette-like structures, and exaggerated maturation characterize Spitz tumors with NTRK1 fusion. Am. J. Surg. Pathol. 2019; 43; 737-746.
Zhao J, Benton S, Zhang B et al. Benign and intermediate-grade melanocytic tumors with BRAF mutations and Spitzoid morphology: a subset of melanocytic neoplasms distinct from melanoma. Am. J. Surg. Pathol. 2022; 46; 476-485.
Vergier B, Prochazkova-Carlotti M, de la Fouchardière A et al. Fluorescence in situ hybridization, a diagnostic aid in ambiguous melanocytic tumors: European study of 113 cases. Mod. Pathol. 2011; 24; 613-623.
Gammon B, Beilfuss B, Guitart J, Gerami P. Enhanced detection of spitzoid melanomas using fluorescence in situ hybridization with 9p21 as an adjunctive probe. Am. J. Surg. Pathol. 2012; 36; 81-88.
Gerami P, Scolyer RA, Xu X et al. Risk assessment for atypical spitzoid melanocytic neoplasms using FISH to identify chromosomal copy number aberrations. Am. J. Surg. Pathol. 2013; 37; 676-684.
Yazdan P, Cooper C, Sholl LM et al. Comparative analysis of atypical Spitz tumors with heterozygous versus homozygous 9p21 deletions for clinical outcomes, histomorphology, BRAF mutation, and p16 expression. Am. J. Surg. Pathol. 2014; 38; 638-645.
Garola R, Singh V. Utility of p16-Ki-67-HMB45 score in sorting benign from malignant Spitz tumors. Pathol. Res. Pract. 2019; 215; 152550.
McAfee JL, Scarborough R, Jia XS et al. Combined utility of p16 and BRAF V600E in the evaluation of spitzoid tumors: superiority to PRAME and correlation with FISH. J. Cutan. Pathol. 2023; 50; 155-168.
Gerami P, Benton S, Zhao J et al. PRAME expression correlates with genomic aberration and malignant diagnosis of Spitzoid melanocytic neoplasms. Am. J. Dermatopathol. 2022; 44; 575-580.